Mucinous Carcinoma of the breast

sonialand

Obsolete, moderators, thanks for your responses.

I already had the MRI, which is why it was seen that I had 5 lesions. On the ultrasound, 4 were seen.

I have had two lesions biopsied. Both have 98% estrogen receptors and one has 85% progesterone receptors and the other 25%.

I have several questions, let's see if you can help me:

Question 1: My biopsied lump feels larger to the touch now, after the biopsy. Do you know if it will return to its original size? It's been three weeks since the biopsy and it's not getting any smaller.

Question 2: I would like to know if there is any way to transform the mastectomy they want to perform on me into a lumpectomy, so instead of removing my entire breast, they only remove the tumors. To do this, I understand that I need them to reduce in size or disappear using some technique. Is there a technique or something that can be done to achieve this: oncothermin, cryoablation, something else that I don't know about?

Question 3: Does anyone have experience with these techniques that I mention: cryoablation or oncothermia (electromagnetic hyperthermia) or with any other that has worked in some way?

Thank you very much for continuing here. I wish one of the old colleagues would come in to tell us that things are going great for her after a long time.

bubbles17

unfortunately I find myself back in the club 7.5 years after my original diagnosis at age 31 of stage 1 grade 3 mucinous (multifocal, no nodal involvement, oncotype score 16. At that time, I was treated with double mastectomy, TC chemo and 4.5 years of Zoladex + armidex (no radiation)
Now at age 38, I have a tiny local recurrence in the fibroadipose tissue between the implant and my skin 2 years after coming off the AIs, which appears to be a local recurrence based on it again being mucinous per biopsy and in the same area as the original tumour cluster.
Still going through the full battery of scans but based on this being caught so early (only just had a clean ultrasound in June where it wasn’t there!) my surgeon has suggested this can just be cut out without implant removal followed by radiation and getting back on the AIs. I would have thought something more aggressive might be in order especially as this recurrence is very close to the skin 0.1mm!
If anyone has been through similar would be grateful to hear what sort of treatment was suggested second time round.
thanks.

obsolete

Sonia, hello friend! What a perplexing situation, to which I regretfully have not much relevant info to add. Higher ER%/PR% tend to be more favorable.  I once had been told some tumors can fill with fluid/blood after biopsy which can contribute to tumor enlargement, as mine did.

If your doctor cannot give you satisfactory answers,  perhaps you could author your own individual thread to solicit feedback on this board. Im not familiar with endothermic or cryotherapy reactions, although the technology sounds fascinating.

Regarding breast reduction, be very careful not to rush into reduction until you're 100% certain there are no remaining occult mucinous malignancies in the breast. A reduction procedure didn't end well for a BC patient I knew who had residual tiny occult malignant tumors in her breast which had been too tiny to be visible on MRI. Radiotherapy, scanning and medicine are at times imperfect, unfortunately, so mitigate your risks.

For whatever it's worth, my double mastectomy was much easier, less painful & more doable for me than lumpectomy, except the drains were an inconvenience for a few days. It's also bought me emotional freedom & peace of mind for these past 10+ years, which is invaluable to my life. Best wishes 💗 in your decision making 🤔

obsolete

Part 2

Cancer patients ought to exercise caution not to "turn off P53 Tumor Suppressing Protein (P53 Gene), one of the key mechanisms the body has to fight off cancer, allowing for the rapid proliferation of cancer cells." -- Dr.Charles Hoffe

Not everyone has high sensitization, so patients will react in different ways.  But it's still best to minimize biological action associated with abnormal cellular signaling. A biophysics PhD had warned that spike protein can bind to ACE2 receptor, estrogen receptor & many others. This action essentially can activate the estrogen receptor, for example. Please discuss with medical teams who understand this or who are willing to admit it 😃

p53 deficiency is common in cancers. Some mRNA can reportedly wake up dormant cancer cells & can trigger Tcell receptors &/or suppress p53.
"BNT162b2 mRNA reprograms adaptive & innate immune responses" Ref 2021 paper by scientists at Radboud Centre in Netherlands. Also some spike protein can damage immune response, so all BC patients need a healthy high oxidative environment. Adequate Vitamin D is important with a clean diet. Wishing everyone well who are navigating new & repeat occurrences in this rodeo.

obsolete

THE BNT162b2 mRNA VACCINE AGAINST SARS-CoV-2 REPROGRAMS BOTH ADAPTIVE AND INNATE IMMUNE RESPONSES
"In conclusion, the mRNA BNT162b2 vaccine induces complex functional reprogramming of innate immune responses, which should be considered in the development and use of this new class of vaccines."
https://www.medrxiv.org/content/10.1101/2021.05.03.21256520v1

SURVIVAL OUTCOMES FOR PATIENTS WITH NONMETASTATIC PURE MUCINOUS BREAST CANCER
— Julia Cipriano, MS
Posted: Friday, August 23, 2024
https://jnccn360.org/breast/medical-literature/survival-outcomes-for-patients-with-nonmetastatic-pure-mucinous-breast-cancer/

obsolete

Bumping for @bubbles17

Because it's noted Bubbles originally had Mixed Mucinous with IDC, perhaps recurrence might be treated as conventional IDC this 2nd time around?? You may possibly receive better exposure on IDC threads for Mixed IDC tumor. I heard a couple Stage-IV MixedMC recurrences had been treated with Taxotere or an AI + Verzenio with favorable responses. Best wishes.

kotchaj

@obsolete ,

I am an IDC with mucinous features and that was my exact treatment. I'm a stage 3, but I did Red Devil, Taxol and 2 years of Verzenio and am on an AI for life.

Amanda

bubbles17

obsolete, thanks for the reply.

My recollection is that my initial biopsy in 2017 was “NST with mucinous features”, which would be treated as IDC, however the full pathology after surgery changed to “invasive mucinous carcinoma”, which I read to be a re-evaluation based on the overall greater % of mucinous they removed.
The path on the biopsy this time says “invasive mucinous” straight off the bat so I’m assuming it will be treated as such

obsolete

Seasons Greetings everyone, hope everyone is doing well.

MIXED MUCINOUS CARCINOMA OF THE BREAST IN YOUNG FEMALE PATIENT: CASE REPORT

https://jogs.one/JoGS_1174/

obsolete

CLINICOPATHOLOGICAL CHARACTERISTICS AND GENOMIC PROFILING OF PURE MUCINOUS BREAST CANCER

https://pubmed.ncbi.nlm.nih.gov/38896982/

"The mechanisms underlying PMC recurrence remain unknown."
"Tumour size, lymph node status and TNM staging differed significantly between recurrent group and non-recurrent group."

"TNM stage is an important prognostic factor in PMC. Although we revealed that regional LN-positive PMCs show increased occurrence of duplication variants at 15q23, 17q23.2 and 20p11.21, and deletion variants at 21p11.2."
"And these alterations were NOT DETECTED in primary tumours of regional LN-negative PMCs."

obsolete

MULTIDISCIPLINARY TREATMENT FOR LOCALLY ADVANCED MUCINOUS BREAST CANCER

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324225/

"17 cm sized exposed tumor covered with pus, necrotic tissue, and mucus occupied the whole right breast..."

"To get favorable local control, the patient thereafter received sequential chemotherapy, i.e., anthracycline-containing chemotherapy followed by bevacizumab plus paclitaxel therapy, resulting in marked tumor shrinkage."

"The patient refused to receive post mastectomy radiotherapy and has been well without any recurrences on fulvestrant and palbociclib therapy for 21 months."

"In the treatment of metastatic breast cancer, it is well known that the addition of bevacizumab to chemotherapy increases side effects without improving overall survival but improves the overall response rate [8, 9]. We, therefore, added bevacizumab to preoperative chemotherapy for favorable tumor shrinkage followed by better local control."

"No tumor regression with the preoperative tamoxifen therapy does not directly imply the inefficacy of tamoxifen therapy against this breast cancer. It, however, is true that tamoxifen did not at least have a strong antitumor effect on this breast cancer. We, therefore, have postoperatively treated the patient with fulvestrant and palbociclib."

"Breast oncologists should note that multidisciplinary treatment including both preoperative chemotherapy and skin defect covering using LDMC flap is a feasible therapeutic option with the intent of favorable local control even for mucinous LABCs."

Happy Holidays everyone and a healthier new year!